Nuclear Medicine and Biology
Volume 34, Issue 3 , Pages 257-265 , April 2007

Biodistribution and planar gamma camera imaging of 123I- and 131I-labeled F(ab′)2 and Fab fragments of monoclonal antibody 14C5 in nude mice bearing an A549 lung tumor

  • Ingrid J.G. Burvenich

      Affiliations

    • Laboratory of Radiopharmacy, University of Ghent, B-9000 Ghent, Belgium
    • Corresponding Author InformationCorresponding author. Tel.: +32 9 2648065; fax: +32 9 2648071.
    • ,
  • Steve Schoonooghe

      Affiliations

    • Department of Biomedical Research, Flanders Institute of Biotechnology (VIB), University of Ghent, B-9000 Ghent, Belgium
    • ,
  • Peter Blanckaert

      Affiliations

    • Laboratory of Radiopharmacy, University of Ghent, B-9000 Ghent, Belgium
    • ,
  • Klaus Bacher

      Affiliations

    • Department of Medical Physics and Radiation Protection, Ghent University, B-9000 Ghent, Belgium
    • ,
  • Liesbet Vervoort

      Affiliations

    • Laboratory of Radiopharmacy, University of Ghent, B-9000 Ghent, Belgium
    • ,
  • Elisabeth Coene

      Affiliations

    • N. Goormaghtigh Institute of Pathology, Ghent University, B-9000 Ghent, Belgium
    • ,
  • Nico Mertens

      Affiliations

    • Department of Biomedical Research, Flanders Institute of Biotechnology (VIB), University of Ghent, B-9000 Ghent, Belgium
    • ,
  • Filip De Vos

      Affiliations

    • Laboratory of Radiopharmacy, University of Ghent, B-9000 Ghent, Belgium
    • ,
  • Guido Slegers

      Affiliations

    • Laboratory of Radiopharmacy, University of Ghent, B-9000 Ghent, Belgium

Received 12 July 2006 ,Revised 6 December 2006 ,Accepted 17 December 2006.

References 

  1. De Potter CR, Schelfhout AM, De Smet FH, Van Damme S, de Ridder L, Dhont E, et al. A monoclonal antibody directed against a human cell membrane antigen prevents cell substrate adhesion and tumor invasion. Am J Pathol. 1994;144:95–103
  2. Coene E, Schelfhout AM, De Ridder L, De Potter CR. Generation of a monoclonal antibody directed against a human cell substrate adhesion molecule and the expression of the antigen in human tissues. Hybridoma. 1997;16:77–83
  3. Burvenich I, Schoonooghe S, Cornelissen B, Blanckaert P, Coene E, Cuvelier C, et al. In vitro and in vivo targeting properties of iodine-123- or iodine-131-labeled monoclonal antibody 14C5 in a non-small cell lung cancer and colon carcinoma model. Clin Cancer Res. 2005;11:7288–7296
  4. Gridelli C. Targeted therapies in the treatment of non small cell lung cancer: reality and hopes. Curr Opin Oncol. 2004;16(2):126–129
  5. Maione P, Rossi A, Airoma G, Ferrara C, Castaldo V, Gridelli C. The role of targeted therapy in non-small cell lung cancer. Crit Rev Oncol Hematol. 2004;51(1):29–44
  6. Reff ME. A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications. Crit Rev Oncol Hematol. 2001;40:25–35
  7. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002;43:693–713
  8. Batra SK, Jain M, Wittel UA, Chauhan SC, Colcher D. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol. 2002;13:603–608
  9. Wahl RL, Parker CW, Philpott GW. Improved radioimaging and tumor localization with monoclonal F(ab′)2. J Nucl Med. 1983;24:316–325
  10. Sharkey RM, Motta-Hennessy C, Pawlyk D, Siegel JA, Goldenberg DM. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res. 1990;50:2330–2336
  11. Hansen HJ, Jones AL, Grebenau R, Kunz A, Goldenberg DM. Labeling of anti-tumor antibodies and antibody fragments with Tc-99m. Cancer Treat Res. 1990;51:233–244
  12. Blumenthal RD, Sharkey RM, Haywood L, Natale AM, Wong GY, Siegel JA, et al. Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies. Cancer Res. 1992;52:6036–6044
  13. Behr TM, Blumenthal RD, Memtsoudis S, Sharkey RM, Gratz S, Becker W, et al. Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal antibody fragments. Clin Cancer Res. 2000;6:4900–4907
  14. Murray JL, Rosenblum MG, Zhang HZ, Podoloff DA, Kasi LP, Curley SA, et al. Comparative tumor localization of whole immunoglobulin G anticarcinoembryonic antigen monoclonal antibodies IMMU-4 and IMMU-4 F(ab′)2 in colorectal cancer patients. Cancer. 1994;73:850–857
  15. Willkomm P, Bender H, Bangard M, Decker P, Grunwald F, Biersack HJ. FDG PET and immunoscintigraphy with 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma. J Nucl Med. 2000;41:1657–1663
  16. Libutti SK, Alexander HR, Choyke P, Bartlett DL, Bacharach SL, Whatley M, et al. A prospective study of 2-[18F] fluoro-2-deoxy-d-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels. Ann Surg Oncol. 2001;8:779–786
  17. Koppe MJ, Postema EJ, Aarts F, Oyen WJ, Bleichrodt RP, Boerman OC. Antibody-guided radiation therapy of cancer. Cancer Metastasis Rev. 2005;24:539–567
  18. Behr TM, Sharkey RM, Juweid ME, Blumenthal RD, Dunn RM, Griffiths GL, et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res. 1995;55:3825–3834
  19. Verel I, Visser GW, Boerman OC, van Eerd JE, Finn R, Boellaard R, et al. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm. 2003;18(4):655–661
  20. Wen YH, Kalff J, Peters RH. Pharmacokinetic modeling in toxicology: a critical perspective. Environ Rev. 1999;7:1–18
  21. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med. 2005;46:115S–127S
  22. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005;23:1137–1146
  23. Schoonjans R, Willems A, Schoonooghe S, Fiers W, Grooten J, Mertens N. Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives. J Immunol. 2000;165(15):7050–7057
  24. Goel A, Colcher D, Baranowska-Kortylewicz J, Augustine S, Booth BJ, Pavlinkova G, et al. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application. Cancer Res. 2000;60:6964–6971
  25. Todorovska A, Roovers RC, Dolezal O, Kortt AA, Hoogenboom HR, Hudson PJ. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J Immunol Methods. 2001;248:47–66
  26. Power BE, Doughty L, Shapira DR, Burns JE, Bayly AM, Caine JM, et al. Noncovalent scFv multimers of tumor-targeting anti-Lewis(y) hu3S193 humanized antibody. Protein Sci. 2003;12:734–747
  27. Olafsen T, Tan GJ, Cheung CW, Yazaki PJ, Park JM, Shively JE, et al. Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel. 2004;17:315–323
  28. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005;23:1126–1136
  29. Steffens MG, Oosterwijk E, Kranenborg MH, Manders JM, Debruyne FM, Corstens FH, et al. In vivo and in vitro characterizations of three 99mTc-labeled monoclonal antibody G250 preparations. J Nucl Med. 1999;40:829–836
  30. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000;60:5237–5243

PII: S0969-8051(07)00003-0

doi: 10.1016/j.nucmedbio.2006.12.006

Nuclear Medicine and Biology
Volume 34, Issue 3 , Pages 257-265 , April 2007

Article Tools

* Image Usage & Resolution